SPI Pharma Corp Ad SPI Pharma Corp Ad

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Phase III Clinical Study of AJM300 for Treatment of Ulcerative Colitis Conducted in Japan (AJM300\/CT3 Study)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Carotegrast Methyl

    Menu

    Carotegrast Methyl

    DEVELOPMENTS

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kissei Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Results of Phase III Clinical Study of AJM300 for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/CT3 Study)

              Details:

              Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.

              Lead Product(s): Carotegrast Methyl

              Therapeutic Area: Gastroenterology Product Name: AJM300

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: EA Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Temad- We think of world-class quality.
              IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
              Post Enquiry
              POST ENQUIRY